NeuroSense: A Hold Ahead Of Phase 2b ALS Data (NASDAQ:NRSN)

Pornpak Khunatorn/iStock via Getty Images


NeuroSense (NASDAQ:NRSN) is a microcap focused on the treatment of neurodegenerative diseases.

It is running a Phase 2b trial in 69 patients diagnosed with ALS, a fast-progressing neurodegenerative disease which is historically difficult to treat, with

Leave a Comment